On the heels of encouraging data from the phase III POLO trial presented at the 2019 ASCO Annual Meeting, Hall stresses that actionable mutations are very common in pancreatic cancer. Research indicates that approximately 10% to 15% of patients with pancreatic cancer have a clinically meaningful genetic alteration in their tumor that is important not only to their disease but also in terms of their family history. Watch here. . .